Impact of Inadequate Empiric Antimicrobial Therapy on Clinical Outcomes of Patients With Escherichia coli or Klebsiella Species Bacteremia

Abstract

This study was conducted to evaluate the effect of inadequate empiric antimicrobial therapy (IEAT) on mortality of patients with Escherichia coli or Klebsiella species bacteremia. Patients with E coli or Klebsiella species bacteremia were retrospectively analyzed to determine the effect of IEAT on 14-day mortality. IEAT of bacteremia was defined as administration of an antimicrobial agent to which the microorganism responsible for the bacteremia was resistant. IEAT was significantly associated with central venous catheter placement, Klebsiella species, and antimicrobial resistance among the 135 patients with E coli or Klebsiella species bacteremia (110 adequate, 25 inadequate). IEAT significantly increased 14-day mortality (32% vs 19%; P = .019). The increased 14-day mortality associated with IEAT was consistent among patients infected with E coli (33% vs 11%) or Klebsiella species (31% vs 15%). Independent risk factors for 14-day mortality in the multivariate analysis included Acute Physiology and Chronic Health Evaluation II (APACHE II) score (odds ratio [OR] 1.16; 95% confidence interval [CI] = 1.07-1.27), IEAT (OR 9.4; 95% CI = 1.36-65.14), and initial imipenem therapy (OR 20.66; 95% CI = 1.48-287.74). Of the 6 patients receiving empiric imipenem/cilastatin, 3 had APACHE II scores ≥ 30 (all 3 of these patients died). The 14-day mortality rate was similar for patients who received IEAT, regardless of whether their therapy was changed (32%) or not (33%). Based on these results and previous studies, greater efforts should be made to identify patients at risk for resistant pathogens before initiating antimicrobial therapy.

Keywords

Inadequate empiric antimicrobial therapy mortality Escherichia coli Klebsiella species bacteremia.

Get full access to this article

View all access options for this article.

References

Ibrahim EH , Sherman G. , Ward S. , Fraser VJ , Kollef MH The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146-155.

Micek ST , Lloyd AE , Ritchie DJ , Reichley RM , Fraser VJ , Kollef MH Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49:1306-1311.

Leibovici L. , Shraga I. , Drucker M. , Konigsberger H. , Samra Z. , Pitlik SD The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998;244:379-386.

Meyer KS , Urban C. , Eagan JA , Berger BJ , Rahal JJ Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins . Ann Intern Med. 1993;119:353-358.

Weinstein MP , Towns ML , Quartey SM , et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults . Clin Infect Dis. 1997 ;24:584-602.

Iregui M. , Ward S. , Sherman G. , Fraser VJ , Kollef MH Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262-268.

Luna CM , Vujacich P. , Niederman MS , et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997;111:676-685.

Wisplinghoff H. , Bischoff T. , Tallent SM , Seifert H. , Wenzel RP , Edmond MB Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study . Clin Infect Dis. 2004 ;39:309-317.

Thomas JK , Forrest A. , Bhavnani SM , et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998;42:521-527.

10.

Rybak MJ Pharmacodynamics: relation to antimicrobial resistance. Am J Med. 2006;119(Suppl 1):S37-S44; discussion S62-S70.

11.

Craig WA

Does the dose matter?

Clin Infect Dis. 2001 ;33 (Suppl 3):S233-S237.

12.

Rao GG Risk factors for the spread of antibiotic-resistant bacteria. Drugs. 1998;55:323-330.

13.

Guillemot D. , Carbon C. , Balkau B. , et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998; 279:365-370.

14.

Scheld WM Maintaining fluoroquinolone class efficacy: review of influencing factors . Emerg Infect Dis. 2003;9:1-9.

15.

Linden PK Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med. 1998;104:24S-33S.

16.

Raymond DP , Pelletier SJ , Crabtree TD , Evans HL , Pruett TL , Sawyer RG Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med. 2003 ;31:1035-1041.

17.

Lautenbach E. , Bilker WB , Brennan PJ Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol. 1999;20:318-323.

18.

Chow JW , Fine MJ , Shlaes DM , et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585-590.

19.

Kim YK , Pai H. , Lee HJ , et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents chemother. 2002 ;46: 1481-1491.

20.

Paterson DL , Ko WC , Von Gottberg A , et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases . Clin Infect Dis. 2004;39:31-37.

21.

Kang CI , Kim SH , Park WB , et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48:4574-4581.

22.

Lautenbach E. , Metlay JP , Bilker WB , Edelstein PH , Fishman NO Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy . Clin Infect Dis. 2005;41:923-929.

23.

National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 5th ed. Wayne, Pa: NCCLS; 2002.

24.

Daikos GL , Kosmidis C. , Tassios PT , et al. Enterobacteriaceae bloodstream infections: presence of integrons, risk factors and outcome. Antimicrob Agents Chemother. 2007;51:2366-2372.

25.

Cosgrove SE , Sakoulas G. , Perencevich EN , Schwaber MJ , Karchmer AW , Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis . Clin Infect Dis. 2003;36:53-59.

26.

Paterson DL , Bonomo RA Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005 ;18:657-686.

27.

Nathisuwan S. , Burgess DS , Lewis JS Jr.Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy. 2001;21:920-928.

28.

American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health care-associated pneumonia. Am J Respir Crit Care Med. 2005 ;171:388-416.

29.

Rex JH , Pappas PG , Karchmer AW , et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221-1228.